AzTrials
AzTrials

AgitationNCT02877108

Naturalistic Adasuve Clinical Trial Study

An observational study of Agitation, run by Mt Sinai Hospital, Chicago at 2 sites in United States.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

There is limited information on the best psychoactive medication to treat agitated patients in the emergency department. The intent of this study is to fill in knowledge gaps in the current practice of treating psychiatric patients in the acute care setting. Read more about this study

Who is it for?
Ages 18 to 65 yearsHealthy volunteers can take part
Conditions the study is for
Agitation
How many people
100 participants
Where
2 sitesUnited States
Study dates
Apr 2016to Apr 2017
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Patients presenting to the emergency department who are or become agitated, requiring medication

Who may be able to join

  • Male and female patients at least 18 years of age and less than 65 years of age
  • Patients must be emergency department patients during time of study
  • All patients will be evaluated by the emergency physician to provide medical clearance- patients must be considered by the emergency physicians to be clinically agitated and to be clinically appropriate candidates for treatment with a medication
  • Each patient, or a surrogate, must understand the nature of the study and must sign an informed consent document
  • English speaking patients

Who cannot join

  • Female patients who are either pregnant or breast-feeding
  • Medically unstable patients
  • Patients who have delirium or dementia
  • Prisoners
  • Patients <18 or >65 years old
  • Non-English speaking patients
  • Contraindications for use for people with asthma, COPD, and other acute respiratory conditions

Trial locations and contacts

2 sites in 1 country.

Leslie Zun, MD contact

773-257-6957

leslie.zun@sinai.org

Jamie Doucet, MPH contact

773-257-6130

jamie.doucet@sinai.org

United States2 sites, 2 recruiting
  • Mount Sinai Hospital

    Chicago, Illinois, 60608

    Jamie Doucet, MPH, 773-257-6130, jamie.doucet@sinai.org

    Recruiting
  • UCSD

    La Jolla, California, 92093

    Michael Wilson, MD, mpwilso1@outlook.com

    Recruiting

Other trials in United States

About this study

Official title: An Observational Study of Anti-Psychotic Medication for the Treatment of Agitation in the Emergency Department

There is limited information on the best psychoactive medication to treat agitated patients in the emergency department. The intent of this study is to fill in knowledge gaps in the current practice of treating psychiatric patients in the acute care setting. The purpose of this study is to determine the best treatment for agitated psychiatric patients in the emergency department.

Read the detailed description

Patients with psychiatric complaints frequently present for evaluation and treatment in emergency departments across the country. In particular, agitation in the emergency department can have life-threatening consequences for both patients and staff, and so patients are frequently given medications to reduce their level of agitation and permit medical examination.

Primary and secondary objectives:

The primary objective of this study is to compare the efficacy and effectiveness of inhaled loxapine (Adasuve) vs. traditional emergency department treatment with intramuscular haloperidol with and without lorazepam in patients who present to the emergency department in an acutely agitated state. The Positive and Negative Syndrome Scale (PANSS-EC), Agitation and Calmness Evaluation Scale (ACES) will be used as measurements of agitation and Barnes akathisia scale will be used as measurements of side effects.

There are five secondary objectives: (1) To assess the level of agitation of psychiatric patients presenting to the emergency department using the PANSS-EC, ACES and Barnes scale; (2) To determine the effect of the level of agitation related to medication treatment and physical restraint using the PANSS-EC; (3) To determine the complication rate of the various medications administered with and without physical restraint; (4) To compare the effectiveness of various pharmacologic agents used in the emergency department for agitation using the delta of agitation over time (5) To determine the effect of the treatment choice on emergency department throughout time using emergency department (ED) throughput time.

Hypothesis:

The hypothesis of this study is to demonstrate superiority of inhaled loxapine (Adasuve) to the traditional anti-psychotic agents (with or without benzodiazepine) in the effectiveness of the treatment of agitation at 15 minute treatment time.

Research design:

The study is an observational convenience (when a research assistant is available), analysis of patients who are given psychoactive medications in the emergency department for agitation during a twelve month period.

The study will determine the level of patient agitation using the Positive and Negative Syndrome Scale (PANSS-EC), Agitation and Calmness Evaluation Scale (ACES) and Barnes akathisia scale. These scales were chosen because of their usage and applicability in studies of the treatment of agitation. The scales will be administered to the patients upon arrival, at fifteen minutes for the first hour and then every half hour for the next 2.5 hours or until the patient leaves the emergency department. The time medications are administered will be documented.

All agitated patients presenting to Mount Sinai Hospital emergency departments who, in the judgment of an ED clinician require treatment. Patients will be treated within the standard of care with the additional of one additional FDA approved medication. All agitated patients presenting to the ED with a psychiatric related complaint, in the judgement of the ED clinician will be prescribed a treatment of choice. The choices will include inhaled loxapine (Adasuve) vs. traditional emergency department treatment with intramuscular haloperidol with and without lorazepam. Clinicians will be free to prescribe any medication that they feel benefits the patient.

Research associates will approach patients who the emergency physician has deemed as agitated and in need of treatment. The research associate will obtain consent from the patient or their surrogate, if patient is not competent to consent to use the patient's information and ensure that the patient meets all study inclusion and no exclusion criteria. If the patient does not have the capacity to consent and no surrogate is available to consent, we will obtain patient data. When the patient gains capacity to consent, they will be approached to consent for use of their information that is being captured. Should these patients refuse consent; all information obtained will be destroyed.

The research associate will obtain consent from the patient or their surrogate and ensure that the patient meets all study inclusion and no exclusion criteria. The researcher will observe the patient and record the level of agitation over a 2.5 hour time period. The research associate will complete all study documents.

All patients will be evaluated by the emergency physician to provide medical clearance. The primary purpose of medical clearance is to determine whether a medical illness is causing or exacerbating the psychiatric condition. The secondary purpose is to identify medical or surgical conditions incidental to the psychiatric problem that may need treatment. The emergency service is responsible for the evaluation and treatment of a patients' agitation. They will determine the need for and choice of treatment option for the patient.

Teva Pharmaceuticals will provide a supply of Loxapine (Adasuve) for the emergency department for the time period of the study. The Principle Investigator has been in communication with the Pharmacy department regarding the storage and distribution of the drug. Please see inclusion/exclusion criteria in "Eligibility". The emergency department staff will be educated about the appropriate use of this education.

The research associate will obtain all necessary data elements either from the patient or the medical record. They will observe and record the PANSS-EC, ACES, and Barnes scores on each enrolled patient every fifteen minutes for the first hour then every half hour for a total of 2.5 hours or until the patient leaves the emergency department. Information will be collected on a data collection sheet that will include basic demographic information on the patient, age, gender, diagnosis, current medication, level of agitation before and after treatment, number of restraints, vital signs, time restraints were applied, type and time medication is administered and complications of therapy. A research associate will complete the data collection sheet and input the data of enrolled patients. The patients' psychiatric diagnosis from the psychiatric service will be noted. The research fellow will complete all study documents. The statistician will perform an analysis of the data looking for statistical significance of the data to the posed questions. Once all data is collected, any identifying information on the patient will be destroyed to ensure patient confidentiality.

Following data collection, the data will be analyzed using commercially-available software packages (such SPSS) to determine agitation reduction using 95% confidence intervals to exclude the margin.

Conditions
Agitation
Medical subject headings
Psychomotor Agitation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT02877108
Study groupRoleWhat they receive
AdasuveThese patients will receive Adasuve for treatment of agitation.
Haloperidol/LorazepamThese patients will receive haloperidol/lorazepam for treatment of agitation.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Reduction of Agitation as Measured by the PANSS-CC

    Patients will receive either an inhaled loxapine or the traditional treatment of haloperidol and will be observed over a three hour period to compare effectiveness of treatment.

    Measured: Three Hours

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Aug 2016 (estimated)
  2. Study startApr 2016
  3. Primary completionApr 2017 (estimated)
  4. Study completionApr 2017 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02877108
Sponsor's protocol ID
15-26
Status last verified
Aug 2016
First submitted
20 Aug 2015
Last updated
24 Aug 2016
Results posted
No
Data monitoring committee
Yes
Individual data sharing
Yes: The investigators will publish findings once data enrollment and data analysis is complete.

Publications

  • Cole JB, Klein LR, Mullinax SZ, Nordstrom KD, Driver BE, Wilson MP. Study Enrollment When "Preconsent" Is Utilized for a Randomized Clinical Trial of Two Treatments for Acute Agitation in the Emergency Department. Acad Emerg Med. 2019 May;26(5):559-566. doi: 10.1111/acem.13673. Epub 2019 Jan 15.

    PubMed 30548977

Questions about this trial

What is this clinical trial studying?

An observational study of Agitation, run by Mt Sinai Hospital, Chicago at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 24 Aug 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Leslie Zun, MD (773-257-6957, leslie.zun@sinai.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Reduction of Agitation as Measured by the PANSS-CC (time frame: Three Hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02877108, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Aug 2016.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in